Global Immune Thrombocytopenia Treatment Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 90

Report ID: 1486

Immune thrombocytopenia (ITP) is a bleeding disorder caused by thrombocytopenia not associated with a systemic disease. Typically, it is chronic in adults, but it is usually acute and self-limited in children. Spleen size is normal in the absence of another underlying condition.
The Immune Thrombocytopenia Treatment market is mostly driven by the factors such as rising prevalence of immune thrombocytopenia (ITP) worldwide, increased government effort to improve healthcare infrastructure, and increased focus on development of novel drugs and therapeutics.
In 2018, the global Immune Thrombocytopenia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Immune Thrombocytopenia Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Immune Thrombocytopenia Treatment development in United States, Europe and China.

The key players covered in this study
CSL
Amgen
F.Hoffmann-La Roche
Kyowa Hakko Kirin
Rigel Pharmaceuticals
Shionogi
Dova Pharmaceuticals
Novartis
Jiangsu Hengrui Pharmaceutical
Shire
Ligand Pharmaceuticals

Market segment by Type, the product can be split into
Intravenous Immunoglobulins
Corticosteroids
Thrombopoietin Receptor Agonists
Others

Market segment by Application, split into
Hospitals and Clinics
Specialty Centers
Research and Academic Institutes
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Immune Thrombocytopenia Treatment status, future forecast, growth opportunity, key market and key players.
To present the Immune Thrombocytopenia Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Immune Thrombocytopenia Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Type (2014-2025)
1.4.2 Intravenous Immunoglobulins
1.4.3 Corticosteroids
1.4.4 Thrombopoietin Receptor Agonists
1.4.5 Others
1.5 Market by Application
1.5.1 Global Immune Thrombocytopenia Treatment Market Share by Application (2014-2025)
1.5.2 Hospitals and Clinics
1.5.3 Specialty Centers
1.5.4 Research and Academic Institutes
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Immune Thrombocytopenia Treatment Market Size
2.2 Immune Thrombocytopenia Treatment Growth Trends by Regions
2.2.1 Immune Thrombocytopenia Treatment Market Size by Regions (2014-2025)
2.2.2 Immune Thrombocytopenia Treatment Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Immune Thrombocytopenia Treatment Market Size by Manufacturers
3.1.1 Global Immune Thrombocytopenia Treatment Revenue by Manufacturers (2014-2019)
3.1.2 Global Immune Thrombocytopenia Treatment Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Immune Thrombocytopenia Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Immune Thrombocytopenia Treatment Key Players Head office and Area Served
3.3 Key Players Immune Thrombocytopenia Treatment Product/Solution/Service
3.4 Date of Enter into Immune Thrombocytopenia Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Immune Thrombocytopenia Treatment Market Size by Type (2014-2019)
4.2 Global Immune Thrombocytopenia Treatment Market Size by Application (2014-2019)

5 United States
5.1 United States Immune Thrombocytopenia Treatment Market Size (2014-2019)
5.2 Immune Thrombocytopenia Treatment Key Players in United States
5.3 United States Immune Thrombocytopenia Treatment Market Size by Type
5.4 United States Immune Thrombocytopenia Treatment Market Size by Application

6 Europe
6.1 Europe Immune Thrombocytopenia Treatment Market Size (2014-2019)
6.2 Immune Thrombocytopenia Treatment Key Players in Europe
6.3 Europe Immune Thrombocytopenia Treatment Market Size by Type
6.4 Europe Immune Thrombocytopenia Treatment Market Size by Application

7 China
7.1 China Immune Thrombocytopenia Treatment Market Size (2014-2019)
7.2 Immune Thrombocytopenia Treatment Key Players in China
7.3 China Immune Thrombocytopenia Treatment Market Size by Type
7.4 China Immune Thrombocytopenia Treatment Market Size by Application

8 Japan
8.1 Japan Immune Thrombocytopenia Treatment Market Size (2014-2019)
8.2 Immune Thrombocytopenia Treatment Key Players in Japan
8.3 Japan Immune Thrombocytopenia Treatment Market Size by Type
8.4 Japan Immune Thrombocytopenia Treatment Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Immune Thrombocytopenia Treatment Market Size (2014-2019)
9.2 Immune Thrombocytopenia Treatment Key Players in Southeast Asia
9.3 Southeast Asia Immune Thrombocytopenia Treatment Market Size by Type
9.4 Southeast Asia Immune Thrombocytopenia Treatment Market Size by Application

10 India
10.1 India Immune Thrombocytopenia Treatment Market Size (2014-2019)
10.2 Immune Thrombocytopenia Treatment Key Players in India
10.3 India Immune Thrombocytopenia Treatment Market Size by Type
10.4 India Immune Thrombocytopenia Treatment Market Size by Application

11 Central & South America
11.1 Central & South America Immune Thrombocytopenia Treatment Market Size (2014-2019)
11.2 Immune Thrombocytopenia Treatment Key Players in Central & South America
11.3 Central & South America Immune Thrombocytopenia Treatment Market Size by Type
11.4 Central & South America Immune Thrombocytopenia Treatment Market Size by Application

12 International Players Profiles
12.1 CSL
12.1.1 CSL Company Details
12.1.2 Company Description and Business Overview
12.1.3 Immune Thrombocytopenia Treatment Introduction
12.1.4 CSL Revenue in Immune Thrombocytopenia Treatment Business (2014-2019)
12.1.5 CSL Recent Development
12.2 Amgen
12.2.1 Amgen Company Details
12.2.2 Company Description and Business Overview
12.2.3 Immune Thrombocytopenia Treatment Introduction
12.2.4 Amgen Revenue in Immune Thrombocytopenia Treatment Business (2014-2019)
12.2.5 Amgen Recent Development
12.3 F.Hoffmann-La Roche
12.3.1 F.Hoffmann-La Roche Company Details
12.3.2 Company Description and Business Overview
12.3.3 Immune Thrombocytopenia Treatment Introduction
12.3.4 F.Hoffmann-La Roche Revenue in Immune Thrombocytopenia Treatment Business (2014-2019)
12.3.5 F.Hoffmann-La Roche Recent Development
12.4 Kyowa Hakko Kirin
12.4.1 Kyowa Hakko Kirin Company Details
12.4.2 Company Description and Business Overview
12.4.3 Immune Thrombocytopenia Treatment Introduction
12.4.4 Kyowa Hakko Kirin Revenue in Immune Thrombocytopenia Treatment Business (2014-2019)
12.4.5 Kyowa Hakko Kirin Recent Development
12.5 Rigel Pharmaceuticals
12.5.1 Rigel Pharmaceuticals Company Details
12.5.2 Company Description and Business Overview
12.5.3 Immune Thrombocytopenia Treatment Introduction
12.5.4 Rigel Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2014-2019)
12.5.5 Rigel Pharmaceuticals Recent Development
12.6 Shionogi
12.6.1 Shionogi Company Details
12.6.2 Company Description and Business Overview
12.6.3 Immune Thrombocytopenia Treatment Introduction
12.6.4 Shionogi Revenue in Immune Thrombocytopenia Treatment Business (2014-2019)
12.6.5 Shionogi Recent Development
12.7 Dova Pharmaceuticals
12.7.1 Dova Pharmaceuticals Company Details
12.7.2 Company Description and Business Overview
12.7.3 Immune Thrombocytopenia Treatment Introduction
12.7.4 Dova Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2014-2019)
12.7.5 Dova Pharmaceuticals Recent Development
12.8 Novartis
12.8.1 Novartis Company Details
12.8.2 Company Description and Business Overview
12.8.3 Immune Thrombocytopenia Treatment Introduction
12.8.4 Novartis Revenue in Immune Thrombocytopenia Treatment Business (2014-2019)
12.8.5 Novartis Recent Development
12.9 Jiangsu Hengrui Pharmaceutical
12.9.1 Jiangsu Hengrui Pharmaceutical Company Details
12.9.2 Company Description and Business Overview
12.9.3 Immune Thrombocytopenia Treatment Introduction
12.9.4 Jiangsu Hengrui Pharmaceutical Revenue in Immune Thrombocytopenia Treatment Business (2014-2019)
12.9.5 Jiangsu Hengrui Pharmaceutical Recent Development
12.10 Shire
12.10.1 Shire Company Details
12.10.2 Company Description and Business Overview
12.10.3 Immune Thrombocytopenia Treatment Introduction
12.10.4 Shire Revenue in Immune Thrombocytopenia Treatment Business (2014-2019)
12.10.5 Shire Recent Development
12.11 Ligand Pharmaceuticals

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details